913983-30-9 Usage
General Description
3-iodo-5-methoxy-1H-pyrrolo[3,2-b]pyridine is a chemical compound with the molecular formula C9H8INO. It is a heterocyclic compound containing a pyrrolopyridine ring system with an iodine atom at position 3 and a methoxy group at position 5. 3-iodo-5-methoxy-1H-pyrrolo[3,2-b]pyridine has potential applications in medicinal chemistry and drug development due to its unique structure and potential biological activities. It is also used as a building block in the synthesis of other organic compounds and pharmaceuticals. The compound is known for its role in organic synthesis and as a key intermediate in the preparation of diverse types of pharmaceuticals and biologically active molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 913983-30-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,9,8 and 3 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 913983-30:
(8*9)+(7*1)+(6*3)+(5*9)+(4*8)+(3*3)+(2*3)+(1*0)=189
189 % 10 = 9
So 913983-30-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H7IN2O/c1-12-7-3-2-6-8(11-7)5(9)4-10-6/h2-4,10H,1H3
913983-30-9Relevant articles and documents
THERAPEUTIC INHIBITORY COMPOUNDS
-
Paragraph 00647, (2018/03/26)
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
4-AZAINDOLE DERIVATIVES
-
Page/Page column 56, (2015/04/22)
4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.
